Rick Bienkowski News Today

J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s approach to AI.

J&J’s cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s approach to...

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market. 

In this article, we will be taking a look at 10 stocks that could 10x over the next 10 years.

Operator: Good morning and welcome to the Intellia Therapeutics First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

In this article, we will take a look at the 12 gene editing stocks with the best long-term potential.

Last year was a period of transition for biotech firms.

In this article, we discuss the 10 stocks that Jim Cramer says you should sell.

In this article, we discuss the 10 undervalued mid-cap stocks that hedge funds love.

In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Greens Redmile Group.